Eli Lilly (LLY 1.16%) currently has several blockbuster drugs on the market -- but lookout investors, there are patent expirations aplenty for this pharma giant ahead. Much like Merck (MRK +1.51%), which is dealing with the recent loss of exclusivity for its top-selling drug Singulair, Lilly has to rely on its pipeline to quickly produce drugs with massive market opportunities. In this video, health-care analyst Max Macaluso dives into the company's most worrying patent expiration of 2013.
What is the one risk investors need to know this year?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo